Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivo Planinc

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Scientific Reports|July 16, 2025
Synchrotron-based X-ray 3D phase contrast imaging and analysis of transmural myocardial tissue from heart failure patientsNikola Skreb, Filip Loncaric, Kan Yan Chloe Li, et al.
European Journal of Heart Failure|May 5, 2026
Update on heart transplantation: a clinical consensus statement of the Advanced Heart Failure Committee of the Heart Failure Association of the European Society of CardiologyDavor Milicic, Ivo Planinc, Stamatis Adamopoulos, et al.
Journal of Cardiac Failure|August 16, 2025
Rationale, design, and baseline characteristics of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 left ventricular assist device recipients (ENVAD-HF)Maja Cikes, Ivo Planinc, Jasper J Brugts, et al.
JACC. Heart Failure|April 28, 2022
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialMaja Cikes, Ivo Planinc, Brian Claggett, et al.
JACC. Heart Failure|September 2, 2025
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy -Primary results of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF)Maja Cikes, Jasper J Brugts, Brian Claggett, et al.
Toxicology|December 14, 2024
Myocardial deposition of aluminum, arsenic, cadmium, and lead accelerates heart failure and alters UPRmt in humansTomo Svagusa, Natalija Matic, Vid Mirosevic, et al.
Heart and Vessels|June 23, 2022
Impact of progressive aortic regurgitation on outcomes after left ventricular assist device implantationHrvoje Gasparovic, Nina Jakus, Jasper J Brugts, et al.
European Journal of Heart Failure|May 4, 2022
Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registryNina Jakus, Jasper J Brugts, Brian Claggett, et al.
ESC Heart Failure|December 22, 2022
Sex-related differences in left ventricular assist device utilization and outcomes: results from the PCHF-VAD registrySumant P Radhoe, Nina Jakus, Jesse F Veenis, et al.
ESC Heart Failure|December 2, 2022
How does age affect outcomes after left ventricular assist device implantation: results from the PCHF-VAD registrySumant P Radhoe, Jesse F Veenis, Nina Jakus, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Scientific Reports|July 16, 2025
Synchrotron-based X-ray 3D phase contrast imaging and analysis of transmural myocardial tissue from heart failure patientsNikola Skreb, Filip Loncaric, Kan Yan Chloe Li, et al.
European Journal of Heart Failure|May 5, 2026
Update on heart transplantation: a clinical consensus statement of the Advanced Heart Failure Committee of the Heart Failure Association of the European Society of CardiologyDavor Milicic, Ivo Planinc, Stamatis Adamopoulos, et al.
Journal of Cardiac Failure|August 16, 2025
Rationale, design, and baseline characteristics of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 left ventricular assist device recipients (ENVAD-HF)Maja Cikes, Ivo Planinc, Jasper J Brugts, et al.
JACC. Heart Failure|April 28, 2022
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialMaja Cikes, Ivo Planinc, Brian Claggett, et al.
JACC. Heart Failure|September 2, 2025
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy -Primary results of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF)Maja Cikes, Jasper J Brugts, Brian Claggett, et al.
Toxicology|December 14, 2024
Myocardial deposition of aluminum, arsenic, cadmium, and lead accelerates heart failure and alters UPRmt in humansTomo Svagusa, Natalija Matic, Vid Mirosevic, et al.
Heart and Vessels|June 23, 2022
Impact of progressive aortic regurgitation on outcomes after left ventricular assist device implantationHrvoje Gasparovic, Nina Jakus, Jasper J Brugts, et al.
European Journal of Heart Failure|May 4, 2022
Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registryNina Jakus, Jasper J Brugts, Brian Claggett, et al.
ESC Heart Failure|December 22, 2022
Sex-related differences in left ventricular assist device utilization and outcomes: results from the PCHF-VAD registrySumant P Radhoe, Nina Jakus, Jesse F Veenis, et al.
ESC Heart Failure|December 2, 2022
How does age affect outcomes after left ventricular assist device implantation: results from the PCHF-VAD registrySumant P Radhoe, Jesse F Veenis, Nina Jakus, et al.
Pageof 3